MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jnci/dju289

Медицинская библиотека · Journal of the National Cancer Institute · 2014

Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.

Munoz Diego, Near Aimee M, van Ravesteyn Nicolien T, Lee Sandra J, Schechter Clyde B, Alagoz Oguzhan, Berry Donald A, Burnside Elizabeth S, Chang Yaojen, Chisholm Gary, de Koning Harry J, Ali Ergun Mehmet, Heijnsdijk Eveline A M, Huang Hui, Stout Natasha K, Sprague Brian L, Trentham-Dietz Amy, Mandelblatt Jeanne S, Plevritis Sylvia K

Сравнительное исследованиеСтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

BACKGROUND

Molecular characterization of breast cancer allows subtype-directed interventions. Estrogen receptor (ER) is the longest-established molecular marker.

METHODS

We used six established population models with ER-specific input parameters on age-specific incidence, disease natural history, mammography characteristics, and treatment effects to quantify the impact of screening and adjuvant therapy on age-adjusted US breast cancer mortality by ER status from 1975 to 2000. Outcomes included stage-shifts and absolute and relative reductions in mortality; sensitivity analyses evaluated the impact of varying screening frequency or accuracy.

RESULTS

In the year 2000, actual screening and adjuvant treatment reduced breast cancer mortality by a median of 17 per 100000 women (model range = 13-21) and 5 per 100000 women (model range = 3-6) for ER-positive and ER-negative cases, respectively, relative to no screening and no adjuvant treatment. For ER-positive cases, adjuvant treatment made a higher relative contribution to breast cancer mortality reduction than screening, whereas for ER-negative cases the relative contributions were similar for screening and adjuvant treatment. ER-negative cases were less likely to be screen-detected than ER-positive cases (35.1% vs 51.2%), but when screen-detected yielded a greater survival gain (five-year breast cancer survival = 35.6% vs 30.7%). Screening biennially would have captured a lower proportion of mortality reduction than annual screening for ER-negative vs ER-positive cases (model range = 80.2%-87.8% vs 85.7%-96.5%).

CONCLUSION

As advances in risk assessment facilitate identification of women with increased risk of ER-negative breast cancer, additional mortality reductions could be realized through more frequent targeted screening, provided these benefits are balanced against screening harms.

Для цитирования: Munoz Diego, Near Aimee M, van Ravesteyn Nicolien T, Lee Sandra J, Schechter Clyde B, Alagoz Oguzhan, Berry Donald A, Burnside Elizabeth S, Chang Yaojen, Chisholm Gary, de Koning Harry J, Ali Ergun Mehmet, Heijnsdijk Eveline A M, Huang Hui, Stout Natasha K, Sprague Brian L, Trentham-Dietz Amy, Mandelblatt Jeanne S, Plevritis Sylvia K. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.. Journal of the National Cancer Institute. 2014. DOI: 10.1093/jnci/dju289.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.